NCT06234423View on ClinicalTrials.gov

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

October 31, 2027

Conditions
Ovarian CancerSolid Tumor
Interventions
DRUG

CUSP06

Antibody drug conjugate (ADC)

Trial Locations (10)

10016

RECRUITING

NYU Cancer Institute Clinical Cancer Center, New York

10021

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

NEXT Oncology, Fairfax

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

SCRI Oncology Partners, Nashville

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

77030

RECRUITING

MD Anderson Cancer Center, Houston

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

06520

RECRUITING

Yale University, New Haven

02115

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

OnCusp Therapeutics, Inc.

INDUSTRY